Fundus vasculopathy
Conditions
Interventions
Compound Xueshuantong capsule treatment group / compound Xueshuantong capsule + western medicine combined treatment group vs Western medicine combined treatment group:None
Sponsors
Tianjin Medical University Eye Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years; 2. Retinopathy (retinal artery occlusion (RAO), retinal vein occlusion (RVO), diabetic retinopathy (DR), hypertensive retinopathy, periretinal phlebitis, age-related macular degeneration (AMD), central serous chorioretinopathy (CSC), anterior ischemic optic neuropathy (AION), its International Classification of Diseases (ICD-11) codes are 9B74.0, 9B74.1, 9B71.0, 9B71.1, 9B78.12, 9B75.0, 9B75.2, 9C40.40; 3. The doctor prescribes Compound Xueshuantong Capsule and/or other medicines for improving microcirculation or fundus vascular disease (Hexuemingmu Tablets, Xuefuzhuyu Capsules, Calcium Dobesilate Capsules, Qiming Granules, Compound Xueshuantong Soft Gel 1. Capsule, Naoxintong Capsule, Tongxinluo Capsule, Pancreatic Kininogenase Enteric-Coated Tablets, Compound Danshen Dropping Pill); 4. There are more than 2 years of follow-up diagnosis and treatment data.
Exclusion criteria
Exclusion criteria: 1. Sudden, painless, significant loss of vision; 2. Those who have undergone retinal photocoagulation, laser photocoagulation or vitrectomy in the early stage; 3. Glaucoma, cataract, ocular trauma and other diseases that affect fundus grading; 4. Uveitis, retinal detachment, optic nerve disease or high myopia; 5. Other endocrine diseases, such as hyperthyroidism, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiovascular event rate;Incidence of renal events;Change in visual acuity from baseline;Change in severity of fundus vascular lesions compared to baseline; | — |
Countries
China
Contacts
Public ContactLi Xiaorong
Tianjin Medical University Eye Hospital
Outcome results
None listed